Natera, Inc. (NASDAQ:NTRA) CFO Sells $719,046.45 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 4,335 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $719,046.45. Following the completion of the transaction, the chief financial officer now directly owns 103,697 shares in the company, valued at approximately $17,200,221.39. The trade was a 4.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Price Performance

NASDAQ:NTRA opened at $176.92 on Monday. The stock has a 50 day moving average of $166.89 and a two-hundred day moving average of $138.50. Natera, Inc. has a 12 month low of $64.74 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.95) earnings per share. Analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Morgan Stanley upped their price target on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Robert W. Baird upped their price objective on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. TD Cowen raised their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Sanford C. Bernstein boosted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.88.

Institutional Investors Weigh In On Natera

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after acquiring an additional 1,883,481 shares in the last quarter. PointState Capital LP boosted its holdings in shares of Natera by 112.0% during the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after purchasing an additional 413,468 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Natera by 42.6% in the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock valued at $144,958,000 after purchasing an additional 328,375 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Natera by 65.6% in the third quarter. ARK Investment Management LLC now owns 687,703 shares of the medical research company’s stock valued at $87,304,000 after purchasing an additional 272,361 shares during the last quarter. Finally, Maverick Capital Ltd. lifted its position in Natera by 25.2% during the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after buying an additional 269,706 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.